Pericyte-coverage of human tumor vasculature and nanoparticle permeability

Liuzhe Zhang, Hiroshi Nishihara, Mitsunobu R. Kano

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Nano drug delivery systems (nanoDDS) are a promising strategy for treatment of human tumors. As indicated by our previous work, the extent of pericyte-coverage of tumor vasculature is important to determining nanoDDS efficacy since intratumoral accumulation of nanoDDS is less in tumor models with pericyte- covered vasculature. Here we investigated the clinical relevance of our previous observations in animal models, by determining pericyte coverage using immunohistochemistry of smooth muscle actin (SMA) with CD34: a vascular endothelial marker, in human tumor tissue samples. The investigation revealed that tumor vasculature coverage by pericytes in pancreatic and diffuse-type gastric cancers was significantly greater than in ovarian, colon, and intestinal-type gastric cancers. The latter group of cancers is easier to treat clinically. These observations are consistent with our previous findings in animal models. On the basis of these findings we believe optimization of nanoDDS delivery should be done depend upon a clear understanding of the effects of pericyte vascular coverage.

Original languageEnglish
Pages (from-to)761-766
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume35
Issue number5
DOIs
Publication statusPublished - 2012 May 1
Externally publishedYes

Fingerprint

Pericytes
Nanoparticles
Permeability
Drug Delivery Systems
Neoplasms
Stomach Neoplasms
Blood Vessels
Animal Models
Intestinal Neoplasms
Smooth Muscle
Actins
Colon
Immunohistochemistry

Keywords

  • Desmoplasia
  • Nano drug delivery system
  • Pericyte
  • Refractory tumor
  • Tumor vasculature

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Pericyte-coverage of human tumor vasculature and nanoparticle permeability. / Zhang, Liuzhe; Nishihara, Hiroshi; Kano, Mitsunobu R.

In: Biological and Pharmaceutical Bulletin, Vol. 35, No. 5, 01.05.2012, p. 761-766.

Research output: Contribution to journalArticle

@article{6fe2727a1b8e4f02a7ae45b34301a253,
title = "Pericyte-coverage of human tumor vasculature and nanoparticle permeability",
abstract = "Nano drug delivery systems (nanoDDS) are a promising strategy for treatment of human tumors. As indicated by our previous work, the extent of pericyte-coverage of tumor vasculature is important to determining nanoDDS efficacy since intratumoral accumulation of nanoDDS is less in tumor models with pericyte- covered vasculature. Here we investigated the clinical relevance of our previous observations in animal models, by determining pericyte coverage using immunohistochemistry of smooth muscle actin (SMA) with CD34: a vascular endothelial marker, in human tumor tissue samples. The investigation revealed that tumor vasculature coverage by pericytes in pancreatic and diffuse-type gastric cancers was significantly greater than in ovarian, colon, and intestinal-type gastric cancers. The latter group of cancers is easier to treat clinically. These observations are consistent with our previous findings in animal models. On the basis of these findings we believe optimization of nanoDDS delivery should be done depend upon a clear understanding of the effects of pericyte vascular coverage.",
keywords = "Desmoplasia, Nano drug delivery system, Pericyte, Refractory tumor, Tumor vasculature",
author = "Liuzhe Zhang and Hiroshi Nishihara and Kano, {Mitsunobu R.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1248/bpb.35.761",
language = "English",
volume = "35",
pages = "761--766",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "5",

}

TY - JOUR

T1 - Pericyte-coverage of human tumor vasculature and nanoparticle permeability

AU - Zhang, Liuzhe

AU - Nishihara, Hiroshi

AU - Kano, Mitsunobu R.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Nano drug delivery systems (nanoDDS) are a promising strategy for treatment of human tumors. As indicated by our previous work, the extent of pericyte-coverage of tumor vasculature is important to determining nanoDDS efficacy since intratumoral accumulation of nanoDDS is less in tumor models with pericyte- covered vasculature. Here we investigated the clinical relevance of our previous observations in animal models, by determining pericyte coverage using immunohistochemistry of smooth muscle actin (SMA) with CD34: a vascular endothelial marker, in human tumor tissue samples. The investigation revealed that tumor vasculature coverage by pericytes in pancreatic and diffuse-type gastric cancers was significantly greater than in ovarian, colon, and intestinal-type gastric cancers. The latter group of cancers is easier to treat clinically. These observations are consistent with our previous findings in animal models. On the basis of these findings we believe optimization of nanoDDS delivery should be done depend upon a clear understanding of the effects of pericyte vascular coverage.

AB - Nano drug delivery systems (nanoDDS) are a promising strategy for treatment of human tumors. As indicated by our previous work, the extent of pericyte-coverage of tumor vasculature is important to determining nanoDDS efficacy since intratumoral accumulation of nanoDDS is less in tumor models with pericyte- covered vasculature. Here we investigated the clinical relevance of our previous observations in animal models, by determining pericyte coverage using immunohistochemistry of smooth muscle actin (SMA) with CD34: a vascular endothelial marker, in human tumor tissue samples. The investigation revealed that tumor vasculature coverage by pericytes in pancreatic and diffuse-type gastric cancers was significantly greater than in ovarian, colon, and intestinal-type gastric cancers. The latter group of cancers is easier to treat clinically. These observations are consistent with our previous findings in animal models. On the basis of these findings we believe optimization of nanoDDS delivery should be done depend upon a clear understanding of the effects of pericyte vascular coverage.

KW - Desmoplasia

KW - Nano drug delivery system

KW - Pericyte

KW - Refractory tumor

KW - Tumor vasculature

UR - http://www.scopus.com/inward/record.url?scp=84861205310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861205310&partnerID=8YFLogxK

U2 - 10.1248/bpb.35.761

DO - 10.1248/bpb.35.761

M3 - Article

VL - 35

SP - 761

EP - 766

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 5

ER -